IMMUNOVANT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 1.65M shares, a 281.49% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 389.58K shares, a 154.97% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 2.12M shares, a 546.34% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 3.20M shares, a 3565.62% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 6.14M shares, a 873.52% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 630.55K shares, a 20.78% decline from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 795.91K shares, a 835.44% increase from fiscal 2023.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 85.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 1.65M shares 10-Q · filed 2026-08-06 | 7.36M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 389.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 6.14M shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 2.12M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | 5.90M shares derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-09-30 | 3.20M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | 4.11M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 433.63K shares 10-Q · filed 2025-08-11 | 1.00M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 152.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | 630.55K shares 10-K · filed 2025-05-29 |
| 2024-12-31 | 327.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-06 | 626.69K shares derived: sum of 4 quarters · filed 2025-02-06 |
| 2024-09-30 | 87.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | 605.61K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 62.81K shares 10-Q · filed 2024-08-06 | 736.91K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 148.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | 795.91K shares 10-K · filed 2024-05-29 |
| 2023-12-31 | 306.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | 674.39K shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2023-09-30 | 218.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | 414.41K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 121.81K shares 10-Q · filed 2023-08-10 | 195.89K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 27.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | 85.08K shares 10-K · filed 2023-05-22 |
| 2022-12-31 | 46.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | |
| 2022-06-30 | 11.00K shares 10-Q · filed 2022-08-05 | |
| 2021-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | 0.00 shares derived: sum of 4 quarters · filed 2023-02-03 |
| 2021-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | 71.87K shares derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-05 | 90.24K shares derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | 114.08K shares 10-K · filed 2021-06-01 |
| 2020-12-31 | 71.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | 114.08K shares derived: sum of 4 quarters · filed 2021-02-16 |
| 2020-09-30 | 18.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | |
| 2020-06-30 | 23.84K shares 10-Q · filed 2020-08-12 | |
| 2020-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | 0.00 shares 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |